Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 851A; 851B; epetirimod esylate; R851; S-30563; S-30563-35-65; TAK-851

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Takeda
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cervical dysplasia; Human papillomavirus infections

Most Recent Events

  • 19 Nov 2013 Profile reviewed - prompted by Wendy's request (via Indu) re CTP18853. Matched R-851 with Epetirimod and requested changes in Thes; only two terminated trials on CT.gov, Takeda's pipeline of October 31, 2013 (TAK-851 no listed); added gel formulation
  • 01 Feb 2009 Discontinued - Phase-II for Cervical dysplasia in Canada (Topical)
  • 01 Feb 2009 Discontinued - Phase-II for Cervical dysplasia in European Union (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top